• Investors
  • News
  • Careers
  • Contact
  • Global Need
    • Vaccines
    • History & Impact
  • Our Solution
    • Oral Vaccines
    • Technology
    • Vaccine Advantages
    • Platform Advantages
  • Pipeline
    • Research & Development
    • Norovirus
    • Influenza
    • RSV
    • HPV
  • About Us
    • Our Mission
    • Our Team
    • Careers
    • Contact
    • Compliance
  • Investors
  • News
  • Careers
  • Contact

Single

John P. Richard

Mr. Richard has served as a member of the Vaxart board of directors since February 2018. Previously, he was a member of the Aviragen board of directors from 2013 to 2018. Mr. Richard is co-founder and Head of Corporate Development for Mereo BioPharma Group plc, a London-based biopharmaceutical company started in 2015. From 2005 until 2015, Mr. Richard was also a partner with Georgia Venture Partners, a seed venture capital firm focused on the biotechnology industry. He currently serves as a non-executive director of Phase4 Partners and serves as a director of Catalyst Biosciences (NASDAQ: CBIO) and QUE Oncology, Inc. Earlier in his career, he headed business development for the public companies SEQUUS Pharmaceuticals, VIVUS and Genome Therapeutics, and was co-founder and CEO of Impath. Mr. Richard received his M.B.A. from the Harvard Business School and a B.S. from Stanford University.

Post navigation

Previous PostPrevious
Next PostNext
Media Contacts

Katie Hogan, WCG
415.658.9745
khogan@wcgworld.com

Samir Singh, Vaxart
908.720.622,4
ssignh@vaxart.com

Get Updates

Subscribe to receive news alerts now.

© 2020 Vaxart, Inc., All rights reserved. Terms of UsePrivacy Policy